High mortality with ST elevation myocardial infarction in a nontrial setting

Area of Science:

• Cardiology
• Clinical Medicine
• Public Health

Background:

• Early mortality following ST elevation myocardial infarction (MI) is declining but remains higher in non-trial settings compared to randomized controlled trials.
• The disparity in mortality may stem from differences in patient characteristics or the utilization of reperfusion strategies.

Purpose of the Study:

• To analyze the management and outcomes of ST elevation MI in a tertiary care hospital setting.
• To compare clinical characteristics and in-hospital mortality between ST elevation MI patients who received reperfusion therapy and those who did not.

Main Methods:

• Retrospective chart review of 115 patients diagnosed with ST elevation MI between July 1999 and June 2000.
• Analysis of reperfusion therapy use (fibrinolysis, primary PCI, rescue PCI) and in-hospital mortality rates.

Main Results:

• 78% of eligible ST elevation MI patients received reperfusion therapy; 22% received none.
• In-hospital mortality was significantly higher in patients not receiving reperfusion therapy (50%) compared to those who did (11%).
• Patients not receiving reperfusion were older, had longer chest pain duration, higher Killip class, and higher TIMI risk scores, with contraindications often noted.

Conclusions:

• Mortality for ST elevation MI is disproportionately higher in patients denied reperfusion therapy.
• Patient characteristics can influence the decision to administer reperfusion therapy.
• Optimizing reperfusion therapy delivery is crucial for improving survival in ST elevation MI patients.